SANTA BARBARA, Calif.--(BUSINESS WIRE)--CytomX Therapeutics, a biotechnology company focused on the development of proteolytically-activated antibodies, today announced the appointment of Mark Rolfe, Ph.D., as chief scientific officer. Dr. Rolfe brings more than 20 years’ experience in oncology drug discovery and development, working with companies including Abbott Laboratories’ Facet Biotech and Millennium Pharmaceuticals. CytomX has also appointed Henry Lowman, Ph.D., to the position of vice president, research; Dr. Lowman joins CytomX after 20 years with Genentech, Inc.
